The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Open accessAbstract
Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire. The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression. The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Challenging Experience Questionnaire (CEQ) was created by Barrett et al. (2016) to quantify challenging experiences under the influence of psychedelics.
“Barrett et al. (2016) created the Challenging Experience Questionnaire (CEQ), which is designed to quantify challenging experiences under the influence of psychedelics (Barrett et al., 2016).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Barrett et al., 2016
The CEQ comprises 26 items rated on a six-point Likert scale and assesses seven factors: grief, fear, death, insanity, isolation, physical distress, and paranoia.
“The CEQ comprised of 26 items, each rated on a six-point Likert scale. Seven factors are assessed, including grief, fear, death, insanity, isolation, physical distress, and paranoia, to provide a phenomenological profile of challenging aspects of experiences with a classical psychedelic.”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Barrett et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hu, L., & Bentler, P. M. (1999) · Structural Equation Modeling A Multidisciplinary Journal · doi:10.1080/10705519909540118 · Cited by 108,788 · cited 11× · see citing works
“Values of SRMR and RMSEA<0.1, and CFI>0.90 (Browne and Cudeck, 1993; Hu”
Influential<b>lavaan</b> : An <i>R</i> Package for Structural Equation Modeling
Rosseel, Y. (2012) · Journal of Statistical Software · doi:10.18637/jss.v048.i02 · Cited by 27,955 · cited 2× · see citing works
“Factorial invariance was assessed in a series of multiplegroup confirmatory factor models using the cfa function in the lavaan toolbox in R (Rossell, 2012), with maximum likelihood estimation.”
MethodComparative fit indexes in structural models.
Bentler, P. M. (1990) · Psychological Bulletin · doi:10.1037/0033-2909.107.2.238 · Cited by 25,266 · cited 8× · see citing works
“Values of SRMR and RMSEA<0.1, and CFI>0.90 (Browne and Cudeck, 1993; Hu”
InfluentialSensitivity of Goodness of Fit Indexes to Lack of Measurement Invariance
Chen, F. F. (2007) · Structural Equation Modeling: A Multidisciplinary Journal · doi:10.1080/10705510701301834 · Cited by 12,217 · cited 3× · see citing works
“change between modeling steps) indicates noninvariance (Chen, 2007).”
InfluentialGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1× · see citing works
“…research on psychedelics has revived their investigation as therapeutic agents (Bogenschutz et al., 2015; Carhart-Harris et al., 2012, 2016a; Griffiths et al., 2016; Grob et al., 2011; Johnson et al., 2014; Ross et al., 2016) and tools to understand psychosis (Schmid et al., 2015;…”
Self-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 3× · see citing works
“, 2011) and anxiety secondary to a life-threatening cancer diagnosis (Griffiths et al., 2016; Ross et al., 2016), and recent large-sample surveys have demonstrated a lower risk for psychological distress and suicidality in those who have endorsed having consumed a classic hallucinogen in the past (Hendricks et al.”
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 16× · see citing works
“…States (APZ) questionnaire) have been widely used in behavioral and neuroimaging research of pharmacologically (Gouzoulis-Mayfrank et al., 2005; Griffiths et al., 2006, 2011; Vollenweider et al., 1998) as well as non-pharmacologically induced altered states of consciousness (Hübner, 2007;…”
InfluentialSelf-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · see citing works
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · cited 2× · see citing works
“…al, 2015; Griffiths et al., 2006, 2011) or spiritual (Kometer et al., 2015) experiences, changes in self-referential processing or “ego dissolution” (Carhart-Harris et al., 2014; Tagliazucchi et al., 2016), altered social processing (Preller et al., 2016), visual imagery (Kaelen et al., 2016),…”
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 3× · see citing works
“Recent empirical work has shown the potential value of psilocybin as a treatment for depression (Carhart-Harris et al., 2016a; Grob et al., 2011) and anxiety secondary to a life-threatening cancer diagnosis (Griffiths et al.”
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · cited 6× · see citing works
“Guidelines have been described to minimize adverse reactions in controlled settings (Johnson et al., 2008), and incidence of lasting symptoms (including psychosis) related to administration of classic hallucinogens in controlled settings is quite low (Griffiths et al., 2006, 2011; Strassman, 1984;…”
InfluentialSelf-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1× · see citing works
“The recent resurgence of empirical research on psychedelics has revived their investigation as therapeutic agents (Bogenschutz et al., 2015; Carhart-Harris et al., 2012, 2016a; Griffiths et al., 2016; Grob et al., 2011; Johnson et al., 2014; Ross et al., 2016) and tools to understand psychosis…”
BackgroundWidaman, K. F., & Reise, S. P. (1997) · The science of prevention: Methodological advances from alcohol and substance abuse research. · doi:10.1037/10222-009 · Cited by 1,146 · see citing works
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1× · see citing works
“…used in behavioral and neuroimaging research of pharmacologically (Gouzoulis-Mayfrank et al., 2005; Griffiths et al., 2006, 2011; Vollenweider et al., 1998) as well as non-pharmacologically induced altered states of consciousness (Hübner, 2007; Kjellgren et al., 2004; Walach and Kaseberg, 1998).”
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · cited 17× · see citing works
“…States (APZ) questionnaire) have been widely used in behavioral and neuroimaging research of pharmacologically (Gouzoulis-Mayfrank et al., 2005; Griffiths et al., 2006, 2011; Vollenweider et al., 1998) as well as non-pharmacologically induced altered states of consciousness (Hübner, 2007;…”
InfluentialSelf-citationPilot study of the 5-HT <sub>2A</sub> R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 7× · see citing works
“Approximately 30% of participants in each of three highly controlled experimental studies (total sample: 69 participants and 204 sessions – Griffiths et al., 2006, 2011; Johnson et al., 2014) involving a high dose of psilocybin (0.”
InfluentialSelf-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · cited 1× · see citing works
“…change (Carhart-Harris et al., 2016b; Lebedev et al., 2016; MacLean et al., 2011), positive mental health outcomes (Hendricks et al., 2015; Johansen and Krebs, 2015), and enduring positive changes in attitudes, mood and behavior (Griffiths et al., 2008, 2011) occasioned by these compounds.”
Self-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895 · cited 2× · see citing works
“, 2015), personality change (Carhart-Harris et al., 2016b; Lebedev et al., 2016; MacLean et al., 2011), positive mental health outcomes (Hendricks et al.”
Self-citationPsychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 6× · see citing works
“…(Strassman, 1995; Strassman et al., 1994) and the various forms of Dittrich’s Altered States of Consciousness questionnaires (Dittrich, 1975, 1998; Studerus et al., 2010), including the Altered States of Consciousness Rating Scale (OAV) and the Five-Dimensional Altered States of Consciousness…”
InfluentialValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637 · cited 2× · see citing works
“, 2016) and mystical experience (Barrett et al., 2015) are positively associated with well-being, it is not completely clear that the items of the ‘death’ subscale of the CEQ (“Profound experience of your own death” and “Feel as if dead or dying”) are collinear with either mystical experience or ego dissolution.”
Self-citationThe Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577 · cited 1× · see citing works
“…Rating Scale (HRS) (Strassman, 1995; Strassman et al., 1994) and the various forms of Dittrich’s Altered States of Consciousness questionnaires (Dittrich, 1975, 1998; Studerus et al., 2010), including the Altered States of Consciousness Rating Scale (OAV) and the Five-Dimensional Altered…”
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 7× · see citing works
“4%) of those participants reported prolonged symptoms (Studerus et al., 2011).”
InfluentialIncreased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · cited 2× · see citing works
“…2006, 2011) or spiritual (Kometer et al., 2015) experiences, changes in self-referential processing or “ego dissolution” (Carhart-Harris et al., 2014; Tagliazucchi et al., 2016), altered social processing (Preller et al., 2016), visual imagery (Kaelen et al., 2016), changes in emotional experience…”
Carbonaro, T. M., Bradstreet, M. P., Barrett, F., Maclean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 494 · cited 9× · see citing works
“A more detailed description of the complete methods, measures, and initial findings of the online survey can be found in the original report (Carbonaro et al., 2016).”
InfluentialSelf-citationPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476 · cited 1× · see citing works
“Participants have also attributed positive change in well-being to their psilocybin experience, and this change in well-being has been shown to correlate positively with mystical experience (Garcia-Romeu et al., 2015) and egodissolution (Nour et al.”
Self-citationEgo-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00269 · Cited by 470 · cited 1× · see citing works
“While the experience of ego dissolution (Nour et al., 2016) and mystical experience (Barrett et al.”
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453 · cited 3× · see citing works
“…used questionnaire instruments assessing the subjective effects of classic hallucinogens are the Hallucinogen Rating Scale (HRS) (Strassman, 1995; Strassman et al., 1994) and the various forms of Dittrich’s Altered States of Consciousness questionnaires (Dittrich, 1975, 1998; Studerus et al.,…”
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 409 · cited 2× · see citing works
“, 2016) and tools to understand psychosis (Schmid et al., 2015; Vollenweider et al., 1998, 2007).”
Prediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369 · cited 2× · see citing works
“…of the importance of set (participant psychological state) and setting (interpersonal and physical environment), acute adverse effects of psychedelics may generally be minimized and successfully managed in research contexts (Johnson et al., 2008; Metzner et al., 1965; Studerus et al., 2012).”
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 360 · cited 3× · see citing works
“, 2016), and recent large-sample surveys have demonstrated a lower risk for psychological distress and suicidality in those who have endorsed having consumed a classic hallucinogen in the past (Hendricks et al., 2015; Johansen and Krebs, 2015).”
Self-citationKraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323 · cited 2× · see citing works
“, 2016), changes in emotional experience (Kaelen et al., 2015; Kraehenmann et al., 2015), personality change (Carhart-Harris et al.”
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · cited 2× · see citing works
“…acid diethylamide (LSD), mescaline, and dimethyltryptamine (DMT; contained in the sacramental beverage ayahuasca) share a primary pharmacological site of action at the serotonin 2a (5HT2a) receptor, and display striking similarities in their subjective effects (Halberstadt, 2015; Nichols, 2016).”
LSD‐induced entropic brain activity predicts subsequent personality change
Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23234 · Cited by 303 · cited 1× · see citing works
“…et al., 2016), changes in emotional experience (Kaelen et al., 2015; Kraehenmann et al., 2015), personality change (Carhart-Harris et al., 2016b; Lebedev et al., 2016; MacLean et al., 2011), positive mental health outcomes (Hendricks et al., 2015; Johansen and Krebs, 2015), and enduring…”
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303 · cited 3× · see citing works
“…of Consciousness Inventory (Pekala, 1986), the Minnesota Multiphasic Personality Inventory (Belleville, 1956), the States of Consciousness Questionnaire (Griffiths et al., 2006, 2011), and the Addiction Research Center Inventory (Griffiths et al., 2006, 2011; Haertzen, 1966; Riba et al., 2001).”
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293 · see citing works
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287 · cited 6× · see citing works
“Clinical literature and anecdotal reports indicate that paranoia is a subjective experience frequently represented in challenging experiences with classic hallucinogens (Cohen, 1960; Griffiths et al., 2006, 2011; Strassman, 1984).”
InfluentialADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE
Strassman, R. (1984) · Journal of Nervous and Mental Disease · doi:10.1097/00005053-198410000-00001 · Cited by 280 · cited 8× · see citing works
“, 2008), and incidence of lasting symptoms (including psychosis) related to administration of classic hallucinogens in controlled settings is quite low (Griffiths et al., 2006, 2011; Strassman, 1984; Studerus et al., 2011).”
InfluentialPsychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 268 · cited 3× · see citing works
“…change (Carhart-Harris et al., 2016b; Lebedev et al., 2016; MacLean et al., 2011), positive mental health outcomes (Hendricks et al., 2015; Johansen and Krebs, 2015), and enduring positive changes in attitudes, mood and behavior (Griffiths et al., 2008, 2011) occasioned by these…”
Haertzen, C. (1966) · Psychological Reports · doi:10.2466/pr0.1966.18.1.163 · Cited by 239 · cited 1× · see citing works
“…of Consciousness Inventory (Pekala, 1986), the Minnesota Multiphasic Personality Inventory (Belleville, 1956), the States of Consciousness Questionnaire (Griffiths et al., 2006, 2011), and the Addiction Research Center Inventory (Griffiths et al., 2006, 2011; Haertzen, 1966; Riba et al., 2001).”
Carhart-Harris, R. L., Leech, R., Williams, T. M., Erritzoe, D., Abbasi, N., Bargiotas, T., Hobden, P., Sharp, D. J., Evans, J., Feilding, A., et al. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.103309 · Cited by 237 · cited 1× · see citing works
“The recent resurgence of empirical research on psychedelics has revived their investigation as therapeutic agents (Bogenschutz et al., 2015; Carhart-Harris et al., 2012, 2016a; Griffiths et al., 2016; Grob et al., 2011; Johnson et al., 2014; Ross et al., 2016) and tools to understand psychosis…”
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., & Kovar, K. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-916185 · Cited by 194 · cited 2× · see citing works
“…(and the preceding Abnormal Mental States (APZ) questionnaire) have been widely used in behavioral and neuroimaging research of pharmacologically (Gouzoulis-Mayfrank et al., 2005; Griffiths et al., 2006, 2011; Vollenweider et al., 1998) as well as non-pharmacologically induced altered states of…”
Effects of serotonin 2A/1A receptor stimulation on social exclusion processing
Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., Scheidegger, M., & Vollenweider, F. X. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524187113 · Cited by 169 · cited 2× · see citing works
“, 2016), altered social processing (Preller et al., 2016), visual imagery (Kaelen et al.”
Freeman, D. H., Dunn, G., Murray, R. M., Evans, N., Lister, R., Antley, A., Slater, M., Godlewska, B. R., Cornish, R., Williams, J. H., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu098 · Cited by 164 · cited 1× · see citing works
“An accepted clinical definition of “paranoia” is “unfounded fears that others intend harm to the individual” (Freeman et al., 2015).”
LSD enhances the emotional response to music
Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4014-y · Cited by 161 · cited 1× · see citing works
“…Tagliazucchi et al., 2016), altered social processing (Preller et al., 2016), visual imagery (Kaelen et al., 2016), changes in emotional experience (Kaelen et al., 2015; Kraehenmann et al., 2015), personality change (Carhart-Harris et al., 2016b; Lebedev et al., 2016; MacLean et al., 2011),…”
Self-citationVollenweider, F., Csomor, P., Knappe, B., Geyer, M., & Quednow, B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301324 · Cited by 159 · cited 1× · see citing works
“…has revived their investigation as therapeutic agents (Bogenschutz et al., 2015; Carhart-Harris et al., 2012, 2016a; Griffiths et al., 2016; Grob et al., 2011; Johnson et al., 2014; Ross et al., 2016) and tools to understand psychosis (Schmid et al., 2015; Vollenweider et al., 1998, 2007).”
Kometer, M., Pokorny, T., Seifritz, E., & Volleinweider, F. X. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4026-7 · Cited by 157 · cited 2× · see citing works
“, 2006, 2011) or spiritual (Kometer et al., 2015) experiences, changes in self-referential processing or “ego dissolution” (Carhart-Harris et al.”
LSD modulates music-induced imagery via changes in parahippocampal connectivity
Kaelen, M., Roseman, L., Kahan, J., Santos-Ribeiro, A., Orbán, C., Lorenz, R., Barrett, F. S., Bolstridge, M., Williams, T., Williams, L., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.018 · Cited by 131 · cited 1× · see citing works
“…or “ego dissolution” (Carhart-Harris et al., 2014; Tagliazucchi et al., 2016), altered social processing (Preller et al., 2016), visual imagery (Kaelen et al., 2016), changes in emotional experience (Kaelen et al., 2015; Kraehenmann et al., 2015), personality change (Carhart-Harris et al.,…”
Self-citationMeasurement of Phenomenological Experience: Phenomenology of Consciousness Inventory
Pekala, R., Steinberg, J., & Kumar, V. K. (1986) · Perceptual and Motor Skills · doi:10.2466/pms.1986.63.2.983 · Cited by 103 · cited 3× · see citing works
“Many other instruments were either used or developed to assess various aspects of subjective experience of hallucinogens, including the Linton-Langs questionnaire (Linton and Langs, 1962), the Abramson questionnaire (Abramson, 1960), the Phenomenology of Consciousness Inventory (Pekala, 1986), the Minnesota Multiphasi…”
The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients
Richards, W. A., Rhead, J., Dileo, F., Yensen, R., & Kurland, A. (1977) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1977.10472020 · Cited by 97 · cited 2× · see citing works
“No items from the MEQ43 were included in the present analysis.”
Hallucinogenic Drugs in Psychiatric Research and Treatment Perspectives and Prospects
Strassman, R. (1995) · Journal of Nervous and Mental Disease · doi:10.1097/00005053-199503000-00002 · Cited by 96 · cited 2× · see citing works
“…two most widely used questionnaire instruments assessing the subjective effects of classic hallucinogens are the Hallucinogen Rating Scale (HRS) (Strassman, 1995; Strassman et al., 1994) and the various forms of Dittrich’s Altered States of Consciousness questionnaires (Dittrich, 1975, 1998;…”
LSD before Leary: Sidney Cohen's Critique of 1950s Psychedelic Drug Research
Novak, S. (1997) · Isis · doi:10.1086/383628 · Cited by 71 · cited 1× · see citing works
“…exceedingly rare ( 0.001% of healthy individuals, and 0.002% of individuals undergoing therapy), however this summary must be viewed tentatively, given numerous limitations including, for example, that none of the reporting investigators had conducted follow-up with their patients (Novak, 1997).”
InfluentialManagement of "bad trips" in an evolving drug scene.
Taylor, R. L., Maurer, J., & Tinklenberg, J. (1970) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.1970.03170290018003 · Cited by 58 · cited 1×
“However, the review noted that emergency department reports (e.g. McCabe, 1977; Taylor et al., 1970) are limited by uncertainty of substance ingested and unknown mental state of the patient prior to putative ingestion of a psychoactive substance.”
Ungerleider, J., Fisher, D. D., & Fuller, M. (1966) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.1966.03110060063015 · Cited by 52 · see citing works
Kjellgren, A., Sundequist, U., Sundholm, U., Norlander, T., & Archer, T. (2004) · Social Behavior and Personality An International Journal · doi:10.2224/sbp.2004.32.2.103 · Cited by 46 · cited 2× · see citing works
“…used in behavioral and neuroimaging research of pharmacologically (Gouzoulis-Mayfrank et al., 2005; Griffiths et al., 2006, 2011; Vollenweider et al., 1998) as well as non-pharmacologically induced altered states of consciousness (Hübner, 2007; Kjellgren et al., 2004; Walach and Kaseberg, 1998).”
A guide to multiple-sample structural equation modeling
Lomax, R. (1983) · Behavior Research Methods · doi:10.3758/bf03203726 · Cited by 46 · cited 1× · see citing works
“…performing a series of multiple-group confirmatory factor analyses, adding more constraints in each sequential model for parameters to be equal across groups and then testing to see whether model fit improves or degrades across sequential models (Kline, 2005; Lomax, 1983; Widaman and Reise, 1997).”
The "bad trip"--the etiology of the adverse LSD reaction.
Ungerleider, J., Fisher, D. D., Fuller, M., & Caldwell, A. (1968) · American Journal of Psychiatry · doi:10.1176/ajp.124.11.1483 · Cited by 45
Placebo reactions in a study of lysergic acid diethylamide (LSD-25).
Linton, H. B., & Langs, R. (1962) · Archives of General Psychiatry · doi:10.1001/archpsyc.1962.01710230037004 · Cited by 28 · cited 2× · see citing works
“…were either used or developed to assess various aspects of subjective experience of hallucinogens, including the Linton-Langs questionnaire (Linton and Langs, 1962), the Abramson questionnaire (Abramson, 1960), the Phenomenology of Consciousness Inventory (Pekala, 1986), the Minnesota…”
MMPI score changes induced by lysergic acid diethylamide (LSD-25).
Belleville, R. E. (1956) · Journal of Clinical Psychology · doi:10.1002/1097-4679(195607)12:3 · Cited by 18 · see citing works
Psychedelic Drug Crises: Toxicity and Therapeutics
McCabe, O. (1977) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1977.10472036 · Cited by 16 · cited 4× · see citing works
“Additional categories of challenging experience have been suggested in the literature, such as the experience of karmic or “astral” experiences, experience of “kundalini” energy, or the experience of such phenomena as age regression (McCabe, 1977).”
InfluentialWalach, H., & Käseberg, E. (1998) · Behavioral Medicine · doi:10.1080/08964289809596388 · Cited by 13 · cited 2× · see citing works
“…used in behavioral and neuroimaging research of pharmacologically (Gouzoulis-Mayfrank et al., 2005; Griffiths et al., 2006, 2011; Vollenweider et al., 1998) as well as non-pharmacologically induced altered states of consciousness (Hübner, 2007; Kjellgren et al., 2004; Walach and Kaseberg, 1998).”
Abramson, H. (1960) · Journal of Mental Science · doi:10.1192/bjp.106.444.1120 · Cited by 7 · cited 2×
“…aspects of subjective experience of hallucinogens, including the Linton-Langs questionnaire (Linton and Langs, 1962), the Abramson questionnaire (Abramson, 1960), the Phenomenology of Consciousness Inventory (Pekala, 1986), the Minnesota Multiphasic Personality Inventory (Belleville, 1956), the…”
Flagged first, then by citations
11 of the 73 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Frecska E Luna LE 2006 The adverse effects of hallucinogens from intramural perspective Neuropsychopharmacologia Hungarica: A Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology 8 4 189 200 17211054
- Metzner R Litwin G Weil G 1965 The relation of expectation and mood to psilocybin reactions: A questionnaire study Psychedelic Review 5 3 3-39
- Pahnke WN Kurland AA Goodman LE Richards WA 1969 LSD-assisted psychotherapy with terminal cancer patients Current Psychiatric Therapies 9 144 152 5348915
- Panksepp J 1998 Affective neuroscience: The foundations of human and animal emotions New York Oxford University Press
Cited by
Sorted by citations
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808 · see citing works
“Recent work has sought to develop and validate a measure that is sensitive to difficult or challenging psychedelic experiences (Barrett et al., 2016; Carbonaro et al., 2016) and there is some evidence that the intensity of such experiences is predictive of positive long-term outcomes, whereas the duration of struggle…”
BackgroundSerotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739 · see citing works
“, 2006) (although acute panic can occur (Barrett et al., 2016; Carbonaro et al., 2016)), yet there is increasing evidence that anxiety can be significantly reduced for a prolonged period after a therapeutically mediated psychedelic drug experience (Gasser et al.”
BackgroundPsychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · see citing works
“More specifically, whereas we saw a trend relationship between challenging experience under a psychedelic and less of an increase in psychological well-being 2 weeks later, others have found evidence that challenging experiences can be therapeutically beneficial (Barrett et al., 2016; Carbonaro et al., 2016).”
BackgroundPredicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417 · see citing works
“The Challenging Experience Questionnaire (CEQ) (Barrett et al., 2016) contains 30 items leading to a total score and seven subscales scores (i.”
BackgroundEmotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413 · see citing works
“Email: leor.roseman13@imperial.ac.uk outcomes, thus suggesting that CE might be counter-therapeutic and perhaps even iatrogenic (Barrett et al., 2016; Carbonaro et al., 2016; Haijen et al., 2018; Roseman et al., 2017), although there are some contradictory findings in this regard, suggesting a more…”
BackgroundResultInfluentialDavis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375 · see citing works
Self-citationAgin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360 · see citing works
“It is also possible that other aspects of the acute psilocybin experience, such as challenging (Barrett et al., 2016) or emotional breakthrough experiences (Roseman et al., 2019), are more influential in explaining long-term changes of psilocybin-assisted psychotherapy.”
BackgroundTowards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313 · see citing works
“However, especially in unsafe settings, psychedelics can also cause “bad trips” involving intense physical and psychological distress [160].”
BackgroundAnderson, B. T., Danforth, A., Daroff, P. R., Stauffer, C., Ekman, E., Agin-Liebes, G., Trope, A., Boden, M. T., Dilley, P. J., Mitchell, J., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100538 · Cited by 284 · see citing works
“Adverse events assessments during the medication visit included spontaneous participant self-report, events observed by clinicians, and symptoms derived from the Challenging Experiences Questionnaire (ChEQ) [33] administered the next day.”
MethodThe use of the psychological flexibility model to support psychedelic assisted therapy
Watts, R., & Luoma, J. B. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.12.004 · Cited by 269 · see citing works
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224 · see citing works
Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214377 · Cited by 247 · see citing works
Self-citationKettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623985 · Cited by 221 · see citing works
“Construct Validity To assess construct validity, bivariate Pearson correlations were calculated between COMS scores, self-constructed items on participant and facilitator-connectedness, and the subscales of validated subjective experience measures taken at each ceremony (IF, PESC, MEQ, CEQ, ASC-VE).”
MethodInfluentialBreeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178 · see citing works
“The use of psychedelics, particularly in uncontrolled circumstances, is associated with acute adverse events (AEs) such as anxiety, panic, dysphoria, paranoia, and/or dangerous behaviors (Barrett et al., 2016; Johnson et al., 2008); such events may contribute to enduring psychological problems (Carbonaro et al.”
BackgroundInfluentialExtended difficulties following the use of psychedelic drugs: A mixed methods study
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R. G., Luke, D. P., Michelle, K., & Prideaux, E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293349 · Cited by 207 · see citing works
“The phenomenology of the acute experience includes fear, grief, feelings of insanity, para-noia, isolation, death, physical distress, confusing and troubling visions [13, 14].”
Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120967878 · Cited by 169 · see citing works
“Although mystical-type experiences are often occasioned by ingesting a psychedelic substance, challenging affective, physiological, and cognitive experiences also sometimes occurs (Barrett et al., 2016, 2017).”
BackgroundMethodInfluentialSelf-citationSloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231154852 · Cited by 165 · see citing works
“After drug effects had subsided on each dosing day, participants completed the Mystical Experience Questionnaire-30 (MEQ-30) (Barrett et al., 2015) and the Challenging Experience Questionnaire (CEQ) (Barrett et al., 2016) to retrospectively rate peak acute drug effects.”
BackgroundMethodInfluentialGarcia‐Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 191 · see citing works
“In addition, people sometimes describe a strong fear that they are dying or going insane (Barrett et al., 2016).”
BackgroundBarrett, F. S., Krimmel, S. R., Griffiths, R. R., Seminowicz, D. A., & Mathur, B. N. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116980 · Cited by 187 · see citing works
“A sense of not being in control of the experience may also manifest, which in some cases may be reflected in the temporary feeling of losing one’s mind or going insane (Barrett et al., 2016).”
Self-citationLearning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Wolff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00005 · Cited by 195 · see citing works
“These challenging experiences(1) (42, 52, 53) are often characterized by extreme fear or panic, and can involve frightening imagery, unsettling body sensations, and the apprehension of immediate threat.”
BackgroundAwe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
Hendricks, P. S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1474185 · Cited by 151 · see citing works
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147 · see citing works
“In this conceptualization, the anxiety or panic that can occur during an adverse encounter with psychedelics can be equated with instances of unmitigated fear (Barrett et al., 2016).”
BackgroundKettner, H., Gandy, S., Haijen, E. C. H. M., & Carhart-Harris, R. L. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16245147 · Cited by 158 · see citing works
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1545024 · Cited by 142 · see citing works
“tually significant psychedelic experiences (35,41).”
BackgroundSelf-citationPeill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066709 · Cited by 141 · see citing works
“Studies have reported mixed results for the relationship between challenging experiences and long-term psychological outcome (Barrett et al., 2016; Carbonaro et al., 2016; Haijen et al., 2018).”
BackgroundMethodResultInfluentialBrouwer, A., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959637 · Cited by 159 · see citing works
“…elevated cortical 5-HT2AR expression (Frokjaer et al., 2008), predicts thought disturbance, blackout and challenging experiences under psychedelics (Barrett et al., 2016, 2017; Lienert and Netter, 1996; although see Studerus et al., 2012) and yet may be reduced after psychedelic therapy (Erritzoe…”
BackgroundDavis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118769063 · Cited by 140 · see citing works
“We included the Challenging Experiences Questionnaire (CEQ), a 26-item self-report measure developed to assess the intensity of challenging experiences one might have after taking a hallucinogen (Barrett et al., 2016).”
InfluentialCarbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133 · see citing works
“Seven subscales and a total score were expressed as percentage ofmaximum possible scores (Barrett et al. 2016).”
MethodSelf-citationHistory repeating: guidelines to address common problems in psychedelic science
van Elk, M., & Fried, E. I. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198466 · Cited by 137 · see citing works
“60 In the long term, such experiences can also cause ontological shocks, resulting in a dramatic shift in one’s religious and spiritual worldviews.”
BackgroundGashi, L., Sandberg, S., & Pedersen, W. (2020) · The International journal on drug policy · doi:10.1016/j.drugpo.2020.102997 · Cited by 132 · see citing works
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124 · see citing works
Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.073 · Cited by 119 · see citing works
Williams, M. T., Davis, A. K., Xin, Y., Sepeda, N. D., Grigas, P. C., Sinnott, S., & Haeny, A. M. (2021) · Drugs: Education, Prevention and Policy · doi:10.1080/09687637.2020.1854688 · Cited by 101 · see citing works
“Challenging experience questionnaire (CEQ; Barrett et al., 2016).”
BackgroundDavis, A. K., Agin-Liebes, G., España, M., Pilecki, B. C., & Luoma, J. B. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1971343 · Cited by 104 · see citing works
Neuroticism is associated with challenging experiences with psilocybin mushrooms
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017) · Personality and Individual Differences · doi:10.1016/j.paid.2017.06.004 · Cited by 98 · see citing works
“Responses from a total of 981 participants who provided useable data for an online survey of challenging experiences with psilocybin mushrooms (Barrett et al., 2016) were included in the current analysis.”
InfluentialSelf-citationGarcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991822 · Cited by 96 · see citing works
“The Challenging Experience Questionnaire (CEQ) is a 26-item measure assessing seven dimensions of psychedelic-occasioned challenging experiences: grief, fear, death, insanity, isolation, physical distress, and paranoia, with each dimension comprising a CEQ subscale (Barrett et al., 2016).”
BackgroundSelf-citationCase analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 121 · see citing works
Set and setting: a randomized study of different musical genres in supporting psychedelic therapy
Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00187 · Cited by 97 · see citing works
Acute Adverse Effects of Therapeutic Doses of Psilocybin
Yerubandi, A., Thomas, J., Bhuiya, N., Harrington, C., Zapata, L. V., & Caballero, J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5960 · Cited by 93 · see citing works
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06083-y · Cited by 88 · see citing works
Perez, N., Langlest, F., Mallet, L., De Pieri, M., Sentissi, O., Thorens, G., Seragnoli, F., Zullino, D., Kirschner, M., Kaiser, S., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.07.011 · Cited by 88 · see citing works
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88 · see citing works
Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1199642 · Cited by 93 · see citing works
“The 26-item Challenging Experience Questionnaire (CEQ) assessed a variety of difficult experiences that could arise during the psilocybin session, comprised of seven factors: grief, fear, death, insanity, isolation, physical distress, and paranoia (49).”
BackgroundSelf-citationCombining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00034 · Cited by 78 · see citing works
A narrative synthesis of research with 5-MeO-DMT
Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211050543 · Cited by 90 · see citing works
“…complete mystical experience (scored as reaching ⩾60% on each of the subscales of the Mystical Experience Questionnaire, MEQ-30; Barrett et al., 2015) with around 37% having challenging experiences (measured by the Challenging Experience Questionnaire; Barrett et al., 2016; Davis et al., 2018a).”
BackgroundSelf-citationPsychedelics and music: neuroscience and therapeutic implications
Barrett, F. S., Preller, K. H., & Kaelen, M. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1484342 · Cited by 88 · see citing works
Self-citationStudy Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Spriggs, M. J., Douglass, H. M., Park, R. J., Read, T., Danby, J. L., de Magalhães, F. J. C., Alderton, K. L., Williams, T. M., Blemings, A., Lafrance, A., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735523 · Cited by 75 · see citing works
Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy.
Strickland, J., Garcia-Romeu, A., & Johnson, M. W. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00187.s001 · Cited by 73
Self-citationKopra, E. I., Ferris, J., Winstock, A., Young, A., & Rucker, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221084063 · Cited by 69 · see citing works
“These are consistent with previous reports of the nature of adverse reactions to psilocybin and other psychedelics and have been discussed in depth elsewhere (Barrett et al., 2016; Van Amsterdam et al., 2011).”
BackgroundResultPhenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience
Lawrence, D. W., Carhart-Harris, R. L., Griffiths, R. R., & Timmermann, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-11999-8 · Cited by 71 · see citing works
Self-citationDavis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T. (2021) · Chronic Stress · doi:10.1177/24705470211035607 · Cited by 67 · see citing works
High dose psilocybin is associated with positive subjective effects in healthy volunteers
Nicholas, C. R., Henriquez, K. M., Gassman, M. C., Cooper, K. M., Muller, D., Hetzel, S., Brown, R. T., Cozzi, N., Thomas, C., & Hutson, P. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780713 · Cited by 67 · see citing works
“…and challenging psychological experiences increase at higher doses (Griffiths et al., 2011; Studerus et al., 2012), it would be informative to measure these experiences (Barrett et al., 2016; Carbonaro et al., 2016) future studies to examine their impact on the rate of mystical experience.”
Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J., Ketzitzidou-Argyri, E., Grabski, M., & Morgan, C. J. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695335 · Cited by 65 · see citing works
“Awe has been proposed as a potential mechanism of action underlying the effects of classic psychedelic-assisted psychotherapy (42) and theoretically overlaps with mystical experiences (43), the small self and ego dissolution (44) and challenging experiences (45) under psychedelics.”
BackgroundStauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00169 · Cited by 65 · see citing works
Replication and extension of a model predicting response to psilocybin
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. M., & Elliott, M. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05279-z · Cited by 77 · see citing works
Sumner, R. L., Chacko, E., McMillan, R. L., Spriggs, M. J., Anderson, C., Chen, J., French, A., Jung, S., Rajan, A., Malpas, G. A., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998321 · Cited by 75 · see citing works
“…with such "challenging experiences" encompassing feelings such as intense grief, fear, death, insanity, isolation, physical distress, and paranoia (Barrett et al., 2016) (note that the specificity of the term "challenging experiences" means they are not simply equivalent to the negative…”
BackgroundMethodStates and Traits Related to the Quality and Consequences of Psychedelic Experiences
Russ, S., Carhart-Harris, R. L., Maruyama, G., & Elliott, M. (2019) · Psychology of Consciousness · doi:10.1037/cns0000169 · Cited by 62 · see citing works
“Some researchers have argued that MEs cannot be measured on a continuous linear scale but instead involve an inflection or transition point into “complete” MEs that appears to be strongly dose-dependent (Barrett et al., 2015; Griffiths et al., 2011). Validated criteria and thresholds for determining the occurrence of…”
BackgroundInfluentialSelf-reported negative outcomes of psilocybin users: A quantitative textual analysis
Bienemann, B., Ruschel, N. S., Campos, M. L. P., Negreiros, M., & Mograbi, D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229067 · Cited by 61 · see citing works
Psychiatric risks for worsened mental health after psychedelic use
Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241232548 · Cited by 60 · see citing works
“Psychedelics do pose a risk of psychologically unpleasant acute experiences, and subjective responses remain unpredictable (Barrett et al., 2016; Byock, 2018; Russ et al., 2019).”
BackgroundWolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58 · see citing works
“…AVE and ACE with CEQ and EBI scores, respectively, lend further support to the construct validity of the APEQ, and add some clarity to the role of challenging (Barrett et al., 2016) and emotional breakthrough experiences (Roseman et al., 2019) in determining longer-term responses to psychedelics.”
BackgroundResultInfluentialUthaug, M. V., Davis, A. K., Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013583 · Cited by 65 · see citing works
“” Previous research (Barrett et al., 2016) has found that the measure produces seven subscales: (1) fear, (2) grief, (3) physical distress, (4) sanity, (5) isolation, (6) death, and (7) paranoia.”
BackgroundInfluentialClinically relevant acute subjective effects of psychedelics beyond mystical experience
Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00345-6 · Cited by 64 · see citing works
“Although subsequent validation in prospective studies generally follows initial investigations 103 , criterion outcomes have been measured using retrospective indices of change 3,9,21,78,79,98 , which are more likely than prospective measures to be vulnerable to placebo and expectancy effects.”
InfluentialSelf-citationReckweg, J., Mason, N., van Leeuwen, C., Toennes, S., Terwey, T., & Ramaekers, J. (2021) · Frontiers in Pharmacology · doi:10.1192/j.eurpsy.2022.1846 · Cited by 56
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
Barba, T., Buehler, S., Kettner, H., Radu, C., Cunha, B. G., Nutt, D. J., Erritzøe, D., Roseman, L., & Carhart-Harris, R. L. (2022) · BJPsych Open · doi:10.1192/bjo.2022.565 · Cited by 59 · see citing works
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Nygart, V. A., Pommerencke, L. M., Haijen, E. C. H. M., Kettner, H., Kaelen, M., Mortensen, E. L., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221101061 · Cited by 74 · see citing works
“High ratings for CE have been associated with both worsened (Barrett et al., 2016; Carbonaro et al., 2016; Haijen et al., 2018; Roseman et al., 2018) and improved long-term mental health outcomes (Carbonaro et al., 2016; Davis et al., 2021b).”
BackgroundInfluentialKopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 61 · see citing works
“Reported negative outcomes were mostly related to emotional states as well as some cognitive functions and appeared largely similar to those observed from recreational use (Barrett et al., 2016; Bienemann et al., 2020; Carbonaro et al., 2016; Gashi et al., 2021; Soares et al., 2022).”
ResultDay trip to hell: A mixed methods study of challenging psychedelic experiences
Johnstad, P. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00155 · Cited by 52 · see citing works
“These experiences also relate to their category of insanity, which included the item “ I was afraid that the state I was in would last forever ” (Barrett et al., 2016, p. 22).”
BackgroundInfluentialPattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 66 · see citing works
“…2019), the Mystical Type Experience Questionnaire (Hood 1975, see also Siegel and Emmert-Aronson 2021), the Psychological Insight Questionnaire (Peill et al. 2022), the Challenging Experience Questionnaire (Barrett et al. 2016), and the Altered States of Consciousness scale (Studerus et al. 2010).”
Safety pharmacology of acute LSD administration in healthy subjects
Holze, F., Caluori, T. V., Vizeli, P., & Liechti, M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05978-6 · Cited by 50 · see citing works
“Negative experiences (so-called bad trips) that are induced by full doses of psychedelics, including severe anxiety, negative feelings, or panic attacks, are sometimes referred to as “challenging experiences” to indicate that these experiences may have some therapeutic value (Barrett et al. 2016).”
BackgroundWeiss, B., Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L., & Erritzoe, D. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.749788 · Cited by 47 · see citing works
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
Goodwin, G., Aaronson, S., Alvarez, O., Carhart-Harris, R., Chai-Rees, J., Croal, M., DeBattista, C., Dunlop, B., Feifel, D., Hellerstein, D., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.061 · Cited by 47 · see citing works
Sexton, J. D., Nichols, C. D., & Hendricks, P. S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00896 · Cited by 46 · see citing works
“org 6 described in terms of psychostimulant effects (20, 29), whereas challenging, emotional breakthrough, and mystical-type experiences appear to underlie the therapeutic outcomes of the classic tryptamine psychedelic psilocybin (16, 66, 67).”
BackgroundLutkajtis, A., & Evans, J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00232 · Cited by 62 · see citing works
Kopra, E. I., Ferris, J., Rucker, J., McClure, B., Young, A., Copeland, C., & Winstock, A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221099650 · Cited by 42 · see citing works
“Without adequate support, subsequent adverse reactions can escalate into, for example, panic attacks, paranoia, aggression, self-harming or accidents, as demonstrated in both the present survey and previous literature (Barrett et al., 2016; Carbonaro et al., 2016; Strassman, 1984).”
ResultMertens, L. J., Koslowski, M., Betzler, F., Evens, R., Gilles, M., Jungaberle, A., Jungaberle, H., Majić, T., Ströhle, A., Wolff, M., et al. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.100104 · Cited by 41 · see citing works
“The association of the subjective experience (Emotional Breakthrough Inventory, EBI; 11D-Altered States of Consciousness, 11D-ASC; Challenging Experience Questionnaire, CEQ) (Barrett et al., 2016; Roseman et al., 2019; Dittrich, 1998) with treatment outcomes is also investigated.”
Bornemann, J., Close, J. B., Spriggs, M. J., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735427 · Cited by 43 · see citing works
“Case reports of persisting perceptual changes exist, though these are rare (54, 55).”
BackgroundWießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Feilding, A., Ribeiro, S. T. G., & Tófoli, L. F. (2021) · Psychological Medicine · doi:10.1017/s0033291721002531 · Cited by 51 · see citing works
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Palitsky, R., Kaplan, D. M., Perna, J., Bosshardt, Z., Maples‐Keller, J. L., Levin-Aspenson, H. F., Zarrabi, A. J., Peacock, C., Mletzko, T., Rothbaum, B. O., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265756 · Cited by 37 · see citing works
“…of psychosocial health, we suggest a set of constructs for the assessment of AEs in clinical trials of PAT, focusing primarily on time points preceding and following the acute dosing session (for characterizations of AEs during the dosing session, see Barrett et al. (2016), Schlag et al. (2022)).”
InfluentialRucker, J., Roberts, C., Seynaeve, M., Young, A. H., Suttle, B., Yamamoto, T., Ermakova, A. O., Dunbar, F., & Wiegand, F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241246857 · Cited by 41 · see citing works
“Generally, less AEs were observed in this study when compared to psychedelic use in uncontrolled circumstances (Barrett et al., 2016; Breeksema et al., 2022; Johnson et al., 2008), reinforcing 5-MeO-DMT administration is safer in a clinical setting.”
BackgroundMethodPsilocybin occasioned mystical‐type experiences
James, E., Robertshaw, T., Hoskins, M., & Sessa, B. (2020) · Human psychopharmacology · doi:10.1002/hup.2742 · Cited by 37 · see citing works
“As such it has been suggested that therapeutic interventions should focus on reducing the duration of a challenging experience rather than reducing its peak difficulty (Barrett et al., 2016; Carbonaro et al., 2016).”
BackgroundSystematic review of psychometric instruments used in research with psychedelics
de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2079108 · Cited by 36 · see citing works
“The CEQ psychometric evaluation was performed on secondary and retrospective data from an online survey of 2085 people who had challenging experiences with psilocybin, The Bad Trip Survey (Carbonaro et al. 2016).”
MethodInfluentialPalmer, M., & Maynard, O. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00662-0 · Cited by 35 · see citing works
“Challenging Experience Questionnaire (CEQ) The CEQ was developed using an Internet survey of those reporting a wide range of challenging experiences while using psilocybin and has been shown to have good internal consistency and external reliability [24].”
MethodAicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33 · see citing works
Wolff, M., Evens, R., Mertens, L. J., Schmidt, C., Beck, J. L., Rutrecht, H. M., Cherniak, A. D., Gründer, G., & Jungaberle, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249698 · Cited by 40 · see citing works
“Correlations between GCMQ scales, APEQ main scales (Acceptance and Avoidance), APEQ ancillary scales (Introspection and Interaction), EBI scores, CEQ total scores, and OBN scores are presented in Table 9.”
BackgroundInfluentialKuc, J., Kettner, H., Rosas, F. E., Erritzøe, D., Haijen, E. C. H. M., Kaelen, M., Nutt, D., & Carhart-Harris, R. L. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05999-1 · Cited by 39 · see citing works
Hovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231200019 · Cited by 33 · see citing works
“Barrett et al. (2016) created the Challenging Experience Questionnaire (CEQ), which is designed to quantify challenging experiences under the influence of psychedelics (Barrett et al., 2016).”
BackgroundSingle-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.
Aaronson, S., van der Vaart, A. D., Miller, T. M., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., & Sackeim, H. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231063 · Cited by 34 · see citing works
McMillan, R. M., & Fernandez, A. V. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221139962 · Cited by 33 · see citing works
“Other psychometric scales such as the Altered States of Consciousness Rating Scale (Dittrich, 1998), Hallucinogenic Rating Scale (Strassman et al., 1994), Hood Mysticism Scale (Hood, 1975), Challenging Experience Questionnaire (Barrett et al., 2016), Psychological Insight Questionnaire (Davis et al., 2021), and Emotio…”
BackgroundBarrett, F. S., Schlienz, N. J., Lembeck, N. A., Waqas, M., & Vandrey, R. G. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0052 · Cited by 40 · see citing works
Self-citationLancelotta, R. L., & Davis, A. K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1737763 · Cited by 33 · see citing works
“We included the 26-item Challenging Experiences Questionnaire (CEQ) to examine the acute challenging psychological or physical experiences that could occur after taking a classic hallucinogen (Barrett et al. 2016).”
MethodDevelopment and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’
McAlpine, R. G., Blackburne, G., & Kamboj, S. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-53829-z · Cited by 51 · see citing works
“Convergent and divergent evidence was evaluated by inspecting the correlations between PPS scores and validated measures that were expected to be positively correlated with psychedelic preparedness (e.g. EBI, MEQ), and measures that were expected to be negatively correlated with psychedelic preparedness (e.g. CEQ).”
BackgroundInfluentialA Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear
Hagsäter, S. M., Pettersson, R., Pettersson, C., Atanasovski, D., Näslund, J., & Eriksson, E. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab040 · Cited by 31 · see citing works
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32 · see citing works
“For example, Barrett et al. [101] argue that while acute adverse psychological reactions to psychedelics are usually benign in controlled settings with proper screening, preparation, and support, they remain a safety concern in uncontrolled settings.”
BackgroundInformed Consent to Psychedelic-Assisted Psychotherapy: Ethical Considerations
Lee, A., Rosenbaum, D., & Buchman, D. Z. (2024) · Canadian journal of psychiatry. Revue canadienne de psychiatrie · doi:10.1177/07067437231225937 · Cited by 31 · see citing works
“15 There has been little systematic research on negative psy-chedelic experiences or “ bad trips, ” the de fi nition of which remains unclear.”
BackgroundPsilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 38 · see citing works
“The Challenging Experience Questionnaire (CEQ) is a widely used self-report instrument that measures challenging experiences during psychedelic sessions.”
MethodDourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 31 · see citing works
“, 2021) and feelings of intense anxiety are often found in therapeutic settings during a portion of the session (Barrett et al., 2016; Griffiths et al., 2006).”
BackgroundFrymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30 · see citing works
Erritzøe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241237870 · Cited by 33 · see citing works
“…measures of the acute experience: the mystical experience questionnaire (MEQ; Barrett et al., 2015), the ego dissolution inventory (EDI; Nour et al., 2016), the emotional breakthrough inventory (EBI; Roseman et al., 2019), and the challenging experience questionnaire (CEQ; Barrett et al., 2016).”
BackgroundMethodInfluentialWeiss, B., Roseman, L., Giribaldi, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 34 · see citing works
“For averaged scores, results were highly convergent with the exception of CEQ Death exhibiting a significant indirect effect (Supplementary Table S8).”
InfluentialChing, T. H. W., Davis, A. K., Xin, Y., & Williams, M. T. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2025960 · Cited by 34 · see citing works
- Authors
- Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Barrett, Frederick S
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-11-19
- Volume
- 30
- Issue
- 12
- Pages
- 1279-1295
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC5549781
- OpenAlex
- W2549202270
- Cited by
- 366
- References
- 73
- Citations by year
- 2026: 43 · 2025: 77 · 2024: 93 · 2023: 41 · 2022: 39 · 2021: 32 · 2020: 15 · 2019: 10 · 2018: 13 · 2017: 3
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889, T32DA007209)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, challenging experiences, bad trips, questionnaire validation, grief, fear, death, paranoia, isolation, physical distress, altered states of consciousness, meaningfulness, spiritual meaning, well-being
- MeSH terms
- Adult, Affect, Agaricales, Anxiety, Depression, Emotions, Female, Hallucinogens, Humans, Male, Psilocybin, Surveys and Questionnaires
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review